← All stocks

Camp4 Therapeutics Corp

CAMP Net buying
CIK 0001736730 #3668 in the set updated 17 Sep 2026
Bought (120 mo)
$80.05M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$2.50M
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$2.50M
6 of 6 sales
Net
+$77.55M
+$77.55M against sales at will

By person

13 insiders · 28 transactions
1.8×

Josh Mandel-Brehm holds only 1.8 times base salary in stock. $1.13M of shares against $600.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Josh Mandel-Brehm last reported holding, valued at $3.96, the price Common Stock was last bought or sold at on the open market here, on 31 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Enavate Sciences GP, LLC entity
10% owner
$15.00M (1)
+$15.00M
3,785,802
$14.99M
5AM Partners VI, LLC entity
10% owner
$14.50M (2)
+$14.50M
2,941,176
$11.65M
Nashat Amir
Director
$12.00M (3)
+$12.00M
197,661
$782.74K
Polaris Management Co. VII, L.L.C. entity
10% owner
$12.00M (3)
+$12.00M
197,661
$782.74K
Northpond Ventures II GP, LLC entity
10% owner
$8.40M (1)
+$8.40M
763,636
$3.02M
AH Equity Partners Bio I, L.L.C. entity
10% owner
$8.00M (2)
+$8.00M
545,454
$2.16M
Schwab Andrew J.
Director
$10.00M (1)
$2.50M (5)
+$7.50M
7,710,486
$30.53M
+216.9%
Gold Kelly
Chief Financial Officer
$60.41K (3)
+$60.41K
86,467
$342.41K
+35.4%
Young Richard A
Director
$52.02K (2)
+$52.02K
186,388
$738.10K
+27.7%
Mandel-Brehm Josh
Chief Executive Officer
$20.81K (2)
+$20.81K
284,968
$1.13M
+4.9%
Maricich Yuri
Chief Medical Officer
$20.81K (2)
+$20.81K
12,611
$49.94K
Tardiff Daniel
Chief Scientific Officer
$8.27K (1)
−$8.27K
0
$0.00
−100.0%
Holtzman Steven H
Director
108,946
$431.43K
+8.9%

No percentages here. This company's share count has moved by a factor of 3.1 over the window, from 20,161,072 to 62,753,200 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 58
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 8
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 6
Transactions with no price 0
Shares from compensation/vesting 15,724,050
History held since 15 Oct 2024